ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0631

Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.

Rudrarpan Chatterjee1, Komal Singh2, Ranjan Gupta3, Sudhir Sinha4 and Amita Aggarwal5, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 3All India Institute of Medical Sciences, New Delhi, Delhi, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, 5Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

Meeting: ACR Convergence 2025

Keywords: Autoantibody(ies), Infection, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) are predisposed to infections due to immune dysregulation. Autoantibodies to cytokines can cause serious infections, including severe COVID-19, by mycobacteria or other intracellular microbes. We describe here antibodies to type I, II and III interferons (IFNα, ω, γ & λ) as a cause for infections in an inception cohort of SLE (INSPIRE) from India.

Methods: Newly diagnosed SLE (SLICC 2012 criteria) within 6 months of disease onset were enrolled in the INSPIRE cohort from 2018-2023. We developed an ELISA for antibodies to IFN α, ω, γ and λ. Baseline sera retrieved from the biobank were tested for these antibodies. Antibody titres were expressed as optical density (OD) and the 95th percentile of antibody titres in healthy-control population was used to develop cutoffs for positivity. Outcomes studied were infections in the initial 2 years of follow up. Serious infections were those that led to hospitalisation or mortality.

Results: A total of 313 patients of SLE (294 females) with a mean age 27.7±10.2 years were enrolled from 2 centres in North India. In addition, sera from 59 healthy controls were also tested for anti IFN antibodies. Antibodies to IFN-α, IFN-ω, IFN- γ and IFN-λ were present in 73 (23.3%), 18 (5.5%), 18 (5.5%) and 30 (9.6%) patients respectively. Eight patients (2.72%) had more than 1 anti-interferon antibodies. In contrast, 3 (5.08%) healthy controls had antibodies to IFN-α, IFN-ω, IFN- γ and IFN-λ each.In the initial 2 years, there were 107 infections, of which 31 were serious infections. Bacterial including mycobacterial infections (79, 25.2%) were most common followed by viral (32, 10.2%) and fungal (15, 4.8%). Herpes zoster (25, 7.9%) was the most common infection followed by tuberculosis (11, 3.5%). No healthy control had history of serious infections.Antibodies to IFN-α were associated with serious infections (OR 2.79, 1.29-6.04), tuberculosis (OR 3.46, 1.03-11.68), viral infections (OR 2.64, 1.23-5.68) and Herpes zoster (OR 3.1, 1.2-8.02), but not with overall infections (OR 1.3, 0.76-2.35), bacterial (OR 1.27, 0.69-2.36) or fungal (OR 1.23, 0.38-3.99) infections. Antibodies to IFN-λ were associated with serious infections (OR 2.93, 1.1-7.83) but not with any subtype of infection. Antibodies to IFN-ω and IFN-γ were not associated with any higher risk of infections.

Conclusion: Antibodies to IFN-α are the most common anti-interferon antibody in an Indian inception cohort of SLE and predispose to serious infections, especially viral infections, Herpes zoster and tuberculosis in the initial 2 years of follow-up.

Supporting image 1


Disclosures: R. Chatterjee: None; K. Singh: None; R. Gupta: None; S. Sinha: None; A. Aggarwal: None.

To cite this abstract in AMA style:

Chatterjee R, Singh K, Gupta R, Sinha S, Aggarwal A. Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/antibodies-to-type-i-and-type-iii-interferons-at-diagnosis-predispose-to-serious-infections-on-follow-up-in-an-inception-cohort-of-sle-inspire-from-india/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-to-type-i-and-type-iii-interferons-at-diagnosis-predispose-to-serious-infections-on-follow-up-in-an-inception-cohort-of-sle-inspire-from-india/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology